Vega Investment Solutions bought a new stake in Revvity Inc. (NYSE:RVTY - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 10,492 shares of the company's stock, valued at approximately $1,167,000.
A number of other institutional investors have also added to or reduced their stakes in RVTY. Paradigm Capital Management Inc. NY bought a new position in Revvity during the second quarter valued at about $11,999,000. Cibc World Market Inc. acquired a new position in Revvity in the 2nd quarter valued at approximately $680,000. Sanctuary Advisors LLC bought a new stake in shares of Revvity in the 2nd quarter worth approximately $315,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Revvity in the 2nd quarter worth approximately $9,696,000. Finally, Clear Harbor Asset Management LLC acquired a new stake in shares of Revvity during the 2nd quarter worth approximately $278,000. 86.65% of the stock is owned by institutional investors and hedge funds.
Revvity Trading Down 1.3%
Shares of RVTY stock opened at $123.08 on Tuesday. The company has a market capitalization of $13.73 billion, a P/E ratio of 58.61, a P/E/G ratio of 2.27 and a beta of 1.07. Revvity Inc. has a 12-month low of $81.22 and a 12-month high of $124.97. The company has a quick ratio of 1.50, a current ratio of 1.80 and a debt-to-equity ratio of 0.36. The firm has a 50-day moving average price of $111.90 and a 200 day moving average price of $100.48.
Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $1.41 earnings per share for the quarter, topping the consensus estimate of $1.21 by $0.20. The firm had revenue of $729.69 million for the quarter, compared to analysts' expectations of $702.96 million. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The company's quarterly revenue was down 1.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.18 earnings per share. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts forecast that Revvity Inc. will post 5.36 earnings per share for the current fiscal year.
Revvity Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Friday, October 23rd will be given a $0.07 dividend. The ex-dividend date is Friday, October 23rd. This represents a $0.28 annualized dividend and a yield of 0.2%. Revvity's payout ratio is presently 13.33%.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on the company. Robert W. Baird set a $117.00 price objective on Revvity in a research report on Wednesday, May 6th. Weiss Ratings raised Revvity from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Thursday, July 30th. Sanford C. Bernstein assumed coverage on shares of Revvity in a research note on Friday, June 26th. They set a "market perform" rating and a $115.00 price target on the stock. Wolfe Research assumed coverage on shares of Revvity in a report on Tuesday, June 2nd. They issued a "peer perform" rating on the stock. Finally, Evercore restated an "outperform" rating on shares of Revvity in a research note on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company. According to data from MarketBeat, Revvity presently has a consensus rating of "Hold" and an average price target of $108.36.
Check Out Our Latest Stock Report on Revvity
About Revvity
(
Free Report)
Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.
Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Revvity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revvity wasn't on the list.
While Revvity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
